Clinical trial
Safety Study of Once a Day ART and Opiate Substitute.
NCT00324688 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00324688 |
|---|---|
| Title | Safety Study of Once a Day ART and Opiate Substitute. |
| Official title | Open-label Multicenter Study to Assess the Efficacy, the Tolerability and the Adherence of a Once Daily (QD) Taken Antiretroviral Therapy (ART) Containing the NtRTI Tenofovir DF 300 mg in Combination With the Best Suitable Once a Day Regimen Being 1 NRTI Plus 1 PI or 1 NRTI Plus 1 NNRTI in… |
| Acronym | 3OD |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Viread |
| Enrollment | 60 |
| Start date | Mar 1, 2003 |
| Completion | Jun 1, 2006 |
| First posted | May 11, 2006 |
| Last update posted | Mar 12, 2014 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: